IL269710A - 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers - Google Patents

2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers

Info

Publication number: IL269710A
Authority: IL; Israel
Prior art keywords: cancers; oxo; inhibitors; compounds; treatment
Prior art date: 2017-03-30

Application number

IL26971019A

Other languages

Hebrew (he)

Other versions

IL269710B2 (en

Original Assignee

Iteos Therapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-03-30

Filing date

2019-09-26

Publication date

2019-11-28

2018-03-28 Priority claimed from ARP180100778A external-priority patent/AR111200A1/en

2018-03-30 Priority claimed from PCT/EP2018/058301 external-priority patent/WO2018178338A1/en

2019-09-26 Application filed by Iteos Therapeutics filed Critical Iteos Therapeutics

2019-11-28 Publication of IL269710A publication Critical patent/IL269710A/en

2023-06-01 Publication of IL269710B2 publication Critical patent/IL269710B2/en

Links

CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical class OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL269710A 2017-03-30 2019-09-26 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers IL269710B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP17163781		2017-03-30
US201762565281P	2017-09-29	2017-09-29
EP17194084		2017-09-29
ARP180100778A AR111200A1 (en)	2017-03-30	2018-03-28	THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS AND METHODS FOR USE IN CANCER TREATMENT
PCT/EP2018/058301 WO2018178338A1 (en)	2017-03-30	2018-03-30	2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers

Publications (2)

Publication Number	Publication Date
IL269710A true IL269710A (en)	2019-11-28
IL269710B2 IL269710B2 (en)	2023-06-01

Family

ID=61911575

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL300149A IL300149A (en)	2017-03-30	2018-03-30	2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
IL269710A IL269710B2 (en)	2017-03-30	2019-09-26	2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
IL300149A IL300149A (en)	2017-03-30	2018-03-30	2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers

Country Status (19)

Country	Link
US (3)	US10995101B2 (en)
EP (2)	EP3601296B1 (en)
JP (2)	JP7197558B2 (en)
KR (2)	KR102640927B1 (en)
CN (3)	CN115991679A (en)
AU (1)	AU2018246355B2 (en)
BR (1)	BR112019020421A8 (en)
CA (1)	CA3058260A1 (en)
DK (1)	DK3601296T3 (en)
ES (1)	ES2926158T3 (en)
HR (1)	HRP20221039T1 (en)
HU (1)	HUE059990T2 (en)
IL (2)	IL300149A (en)
LT (1)	LT3601296T (en)
MX (2)	MX2019011743A (en)
PL (1)	PL3601296T3 (en)
RS (1)	RS63557B1 (en)
RU (1)	RU2019134724A (en)
SI (1)	SI3601296T1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2020527593A (en)	2017-07-18	2020-09-10	ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎＢｉｏＩｎｃ．	1,8-naphthylidinone compounds and their use
US11028058B2 (en)	2017-07-18	2021-06-08	Nuvation Bio Inc.	Heterocyclic compounds as adenosine antagonists
WO2020053263A1 (en) *	2018-09-11	2020-03-19	Iteos Therapeutics S.A.	Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
US11376255B2 (en)	2018-09-11	2022-07-05	iTeos Belgium SA	Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
US11427594B2 (en)	2018-09-27	2022-08-30	iTeos Belgium SA	Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers
WO2020150674A1 (en)	2019-01-18	2020-07-23	Nuvation Bio Inc.	Heterocyclic compounds as adenosine antagonists
JP2022523473A (en)	2019-01-18	2022-04-25	ニューベイション・バイオ・インコーポレイテッド	1,8-naphthylididinone compounds and their use
CN114539265B (en) *	2022-03-02	2023-07-21	中山大学	A2A-targeting benzimidazolopyrazine-3-carboxamides and their tumour immune function

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6448253B1 (en)	1998-09-16	2002-09-10	King Pharmaceuticals Research And Development, Inc.	Adenosine A3 receptor modulators
US6921825B2 (en)	1998-09-16	2005-07-26	King Pharmaceuticuals Research & Development, Inc.	Adenosine A3 receptor modulators
US20080070932A1 (en) *	2003-04-09	2008-03-20	Chi Vu	Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same
WO2005103055A1 (en) *	2004-04-21	2005-11-03	Schering Corporation	PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
WO2007140181A2 (en)	2006-05-26	2007-12-06	King Pharmaceuticals Research And Development, Inc.	Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist
US7723343B2 (en) *	2007-03-30	2010-05-25	King Pharmaceuticals Research And Development, Inc.	Adenosine A2A receptor antagonists
US20090047243A1 (en)	2007-07-17	2009-02-19	Richard Rickles	Combinations for the treatment of b-cell proliferative disorders
WO2011112687A2 (en)	2010-03-10	2011-09-15	Kalypsys, Inc.	Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2012038980A2 (en)	2010-09-24	2012-03-29	Advinus Therapeutics Limited	Fused tricyclic compounds as adenosine receptor antagonist
WO2012055015A1 (en)	2010-10-26	2012-05-03	Alberta Health Services	Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
WO2012135084A1 (en) *	2011-03-31	2012-10-04	Merck Sharp & Dohme Corp.	METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US10399962B2 (en)	2017-01-20	2019-09-03	Arcus Biosciences, Inc.	Azolopyrimidine for the treatment of cancer-related disorders
TWI801372B (en)	2017-03-30	2023-05-11	比利時商艾特歐斯比利時有限公司	Thiocarbamate derivatives as a2a inhibitors and methods for use in the treatment of cancers
CN118001282A (en)	2017-12-19	2024-05-10	因佩蒂斯生物科学有限公司	Pharmaceutical composition for cancer treatment
WO2020053263A1 (en)	2018-09-11	2020-03-19	Iteos Therapeutics S.A.	Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
US11427594B2 (en)	2018-09-27	2022-08-30	iTeos Belgium SA	Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers
JP2022503879A (en)	2018-09-27	2022-01-12	アイテオベルギウムエスエー	Use of ENT family transporter inhibitors in the treatment of cancer and their combination with adenosine receptor antagonists

2018
- 2018-03-30 CN CN202211658370.5A patent/CN115991679A/en active Pending
- 2018-03-30 RS RS20220794A patent/RS63557B1/en unknown
- 2018-03-30 KR KR1020197031322A patent/KR102640927B1/en active IP Right Grant
- 2018-03-30 DK DK18716193.0T patent/DK3601296T3/en active
- 2018-03-30 RU RU2019134724A patent/RU2019134724A/en not_active Application Discontinuation
- 2018-03-30 MX MX2019011743A patent/MX2019011743A/en unknown
- 2018-03-30 BR BR112019020421A patent/BR112019020421A8/en unknown
- 2018-03-30 KR KR1020247005971A patent/KR20240027885A/en active Application Filing
- 2018-03-30 PL PL18716193.0T patent/PL3601296T3/en unknown
- 2018-03-30 ES ES18716193T patent/ES2926158T3/en active Active
- 2018-03-30 EP EP18716193.0A patent/EP3601296B1/en active Active
- 2018-03-30 CA CA3058260A patent/CA3058260A1/en active Pending
- 2018-03-30 LT LTEPPCT/EP2018/058301T patent/LT3601296T/en unknown
- 2018-03-30 JP JP2020503355A patent/JP7197558B2/en active Active
- 2018-03-30 CN CN201880034926.9A patent/CN110678472B/en active Active
- 2018-03-30 AU AU2018246355A patent/AU2018246355B2/en active Active
- 2018-03-30 SI SI201830747T patent/SI3601296T1/en unknown
- 2018-03-30 IL IL300149A patent/IL300149A/en unknown
- 2018-03-30 EP EP22165965.9A patent/EP4112623A1/en active Pending
- 2018-03-30 CN CN202211706953.0A patent/CN115873022A/en active Pending
- 2018-03-30 HR HRP20221039TT patent/HRP20221039T1/en unknown
- 2018-03-30 HU HUE18716193A patent/HUE059990T2/en unknown
2019
- 2019-03-14 US US16/354,022 patent/US10995101B2/en active Active
- 2019-09-26 IL IL269710A patent/IL269710B2/en unknown
- 2019-09-30 MX MX2022005298A patent/MX2022005298A/en unknown
2020
- 2020-08-14 US US16/993,897 patent/US20210198281A1/en not_active Abandoned
2022
- 2022-09-21 US US17/949,595 patent/US20230159564A1/en active Pending
- 2022-12-15 JP JP2022199962A patent/JP2023027282A/en active Pending

Also Published As

Publication number	Publication date
AU2018246355B2 (en)	2021-12-09
US10995101B2 (en)	2021-05-04
CN115991679A (en)	2023-04-21
RU2019134724A3 (en)	2021-06-28
IL300149A (en)	2023-03-01
CN115873022A (en)	2023-03-31
RU2019134724A (en)	2021-04-30
HRP20221039T1 (en)	2022-11-11
DK3601296T3 (en)	2022-08-29
EP3601296A1 (en)	2020-02-05
US20230159564A1 (en)	2023-05-25
BR112019020421A2 (en)	2020-04-28
EP4112623A1 (en)	2023-01-04
HUE059990T2 (en)	2023-01-28
LT3601296T (en)	2022-09-26
BR112019020421A8 (en)	2022-11-08
KR102640927B1 (en)	2024-02-27
JP2023027282A (en)	2023-03-01
ES2926158T3 (en)	2022-10-24
CN110678472A (en)	2020-01-10
IL269710B2 (en)	2023-06-01
AU2018246355A1 (en)	2019-10-17
JP7197558B2 (en)	2022-12-27
CA3058260A1 (en)	2018-10-04
US20210198281A1 (en)	2021-07-01
KR20190141156A (en)	2019-12-23
EP3601296B1 (en)	2022-05-25
SI3601296T1 (en)	2022-10-28
CN110678472B (en)	2023-01-24
US20190276473A1 (en)	2019-09-12
PL3601296T3 (en)	2022-10-10
MX2019011743A (en)	2020-01-20
KR20240027885A (en)	2024-03-04
TW202344508A (en)	2023-11-16
RS63557B1 (en)	2022-10-31
MX2022005298A (en)	2022-05-26
JP2020512407A (en)	2020-04-23

Publication	Publication Date	Title
HK1249524A1 (en)	2018-11-02	Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
IL269710A (en)	2019-11-28	2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
IL272948A (en)	2020-04-30	Enpp1 inhibitors and their use for the treatment of cancer
HK1256283A1 (en)	2019-09-20	Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
ZA201807810B (en)	2021-04-28	Adenosine derivatives for use in the treatment of cancer
IL258979B (en)	2022-06-01	Use of pyrimidine and pyridine derivatives in the treatment of cancer
IL266198A (en)	2019-06-30	Liposomal formulation for use in the treatment of cancer
IL247586A0 (en)	2016-11-30	Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
IL280587B (en)	2021-10-31	Flurocytidine derivatives and its composition for the treatment of cancer
HK1250161B (en)	2020-05-15	6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
IL253933A0 (en)	2017-10-31	Pyrimidine derivatives for use in the treatment of cancer
EP3440052C0 (en)	2023-10-25	Compounds for use in the treatment of cancer
IL269121A (en)	2019-11-28	Usl-311 for use in the treatment of cancer
PT3601296T (en)	2022-08-30	2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers